<DOC>
	<DOCNO>NCT00123370</DOCNO>
	<brief_summary>The study aim evaluate safety efficacy modafinil ( 200 mg/day ) 10 week plus tailored cognitive behavioural therapy program treatment methamphetamine dependence .</brief_summary>
	<brief_title>Trial Modafinil Methamphetamine Dependence</brief_title>
	<detailed_description>Modafinil novel wake promote agent approve Australia treatment narcolepsy . Preliminary study suggest modafinil may value treatment psychostimulant dependence positive effect mood , sleep pattern , concentration , fatigue drug craving . It appear well tolerate low abuse potential . Sixty dependent methamphetamine user allocate 2 equal group . The experimental group receive modafinil 200 mg/day 10 week tailor cognitive behavioural therapy program . The control group receive placebo equivalent condition . Primary outcome group comparison methamphetamine negative urine sample 10 week study period . Adverse event , side effect , compliance , retention self report health , psychosocial drug use also compare study group .</detailed_description>
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>Diagnostic Statistical Manual Mental DisordersFourth Edition ( DSMIV ) amphetamine dependence diagnosis Amphetamine positive urine sample intake Regular current amphetamine use ( 23 day per week ) Aged 18 year old Pregnant nursing female Hazardous concurrent uncontrolled physical mental illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Modafinil</keyword>
	<keyword>Amphetamine Dependence</keyword>
	<keyword>Randomised placebo-controlled trial</keyword>
</DOC>